BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Zinger Key Points
  • BofA Analyst initiated coverage of Arcellx with a Buy rating and a price target of $24.
  • The analyst says the company takes a compelling approach that involves engineering CARTs using a novel synthetic binding scaffold.

Arcellx ACLX is advancing  into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

The Arcellx Analyst: Jason Gerberry initiated coverage of Arcellx with a Buy rating and a price target of $24.

The Arcellx Thesis: The company takes a compelling approach that involves engineering CARTs using a novel synthetic binding scaffold, Gerberry said in the initiation note.

“ACLX’ approach with its lead ddBCMA (in Ph1/2) has shown promise reducing toxicity without trading off efficacy vs. BCMA leaders,” he wrote.

“We look ahead to ASH ’22 as an important de-risking event that could position ddBCMA as an attractive late-mover in a large market,” the analyst added.

Also Read: The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight

"We are also excited about ACLX’ ability to leverage D-domain engineering through programs using its ARC-SparX technology, potentially expanding the frontier of CART to dosable and controllable CARTs designed to be activated only when combined with SparX proteins; ARC-SparX moves into the clinic in ’22 with potential to address indications where toxicity and/or antigen heterogeneity have limited CART development," Gerberry further mentioned.

ACLX Price Action: Shares of Arcellx had declined by 10.55% to $17.12 at the time of publication Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationSmall CapAnalyst RatingsBofA SecuritiesJason Gerberry
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!